Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics Licenses High-Content Screening Patents to GE Healthcare

NEW YORK, June 22 (GenomeWeb News) - Cellomics has non-exclusively licensed its high-content screening patents to GE Healthcare and has agreed to allow GE Healthcare to sublicense these patent rights to pharmaceutical companies, the company said today.


Financial details of the two agreements were not disclosed.


Cellomics, of Pittsburgh, Pa., said it has over 30 issued or allowed patents and an additional 30 patents pending in high content screening, an type of cellular assay it invented and defined.


GE Healthcare was created from the combination of GE Medical Systems and Amersham Biosciences, after Amersham's acquisition by GE.


The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.